Nightingale as an investment
Financial information
Share and shareholders
Governance
- Governance principles
- General Meeting
- Annual General Meeting 2025
- Board of Directors
- Management Team
- Remuneration
- Risk management
- Insider management
- Managers' transactions
- Flagging notifications
- Auditor
- Articles of Association
- Code of Conduct
- Stock Exchange Releases
- Company releases
- Press releases
- Managers' transactions
- Flagging notifications
- En
- Fi
Stock exchange releases
- Nightingale Health strengthens its commercial operations with new EMEA appointment - Jun 13, 2025
- Nightingale Health’s Board of Directors resolved on new stock option program - Jun 09, 2025
- Changes in Nightingale Health Plc’s Management Team - May 02, 2025
- Conversion of Nightingale Health Plc’s Series A shares to Series B shares - Apr 23, 2025
- Trading in Nightingale Health's B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US - Mar 21, 2025
- Nightingale Health Plc's listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025 - Mar 18, 2025
- The Finnish Financial Supervisory Authority has approved Nightingale Health Plc's Finnish prospectus - Mar 17, 2025
- Nightingale Health establishes ADR program in the US - trading in Company's B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US - Mar 17, 2025
- Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki - Mar 12, 2025